These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27979047)

  • 1. Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy.
    Boccara F; Miantezila Basilua J; Mary-Krause M; Lang S; Teiger E; Steg PG; Funck-Brentano C; Girard PM; Costagliola D; Cohen A; Guiguet M;
    Am Heart J; 2017 Jan; 183():91-101. PubMed ID: 27979047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends and predictors of high-intensity statin therapy and LDL-C goal achievement among Thai patients with acute coronary syndrome.
    Wongsalap Y; Jedsadayanmata A
    J Cardiol; 2020 Mar; 75(3):275-281. PubMed ID: 31519405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Valentino M; Al Danaf J; Panakos A; Ragupathi L; Duffy D; Whellan D
    Am Heart J; 2016 Nov; 181():130-136. PubMed ID: 27823684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes.
    Gencer B; Auer R; Nanchen D; Räber L; Klingenberg R; Carballo D; Blum M; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F; Rodondi N
    Atherosclerosis; 2015 Mar; 239(1):118-24. PubMed ID: 25585031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
    Schwartz GG; Abt M; Bao W; DeMicco D; Kallend D; Miller M; Mundl H; Olsson AG
    J Am Coll Cardiol; 2015 Jun; 65(21):2267-75. PubMed ID: 26022813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome.
    Nakahashi T; Tada H; Sakata K; Yakuta Y; Tanaka Y; Nomura A; Gamou T; Terai H; Horita Y; Ikeda M; Namura M; Takamura M; Hayashi K; Yamagishi M; Kawashiri MA
    Heart Vessels; 2018 Jul; 33(7):695-705. PubMed ID: 29288404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate effect of fluvastatin on lipid levels in acute coronary syndrome.
    Ostadal P; Alan D; Vejvoda J; Cepova J; Kukacka J; Blasko P; Martinkovicova L; Vojacek J
    Mol Cell Biochem; 2007 Dec; 306(1-2):19-23. PubMed ID: 17653509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal patterns of lipid testing and statin therapy in acute coronary syndrome patients (from the Canadian GRACE Experience).
    Elbarouni B; Banihashemi SB; Yan RT; Welsh RC; Kornder JM; Wong GC; Anderson FA; Spencer FA; Grondin FR; Goodman SG; Yan AT;
    Am J Cardiol; 2012 May; 109(10):1418-24. PubMed ID: 22381155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002-2010.
    Gottlieb S; Kolker S; Shlomo N; Matetzky S; Leitersdorf E; Segev A; Goldenberg I; Tzivoni D; Weisz G; Moriel M
    Int J Cardiol; 2016 May; 210():133-8. PubMed ID: 26945433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
    Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
    Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients.
    Banach M; Dinca M; Ursoniu S; Serban MC; Howard G; Mikhailidis DP; Nicholls S; Lip GYH; Glasser S; Martin SS; Muntner P; Rysz J; Toth PP; Sahebkar A;
    Pharmacol Res; 2016 Sep; 111():343-356. PubMed ID: 27350264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.